Novartis finally announces Sandoz review and reflects on solid quarter

26 October 2021

After years of questions about the future of its generics and biosimilars business Sandoz, Swiss pharma giant Novartis (NOVN: VX) has finally announced a strategic review of the unit.

The company made the announcement in presenting its financial results for the third quarter of 2021 and said that the review will explore all options, ranging from retaining the business to separation, in order to determine how to best maximize value for shareholders.

"We remain confident in the strength of our pipeline"Sandoz is one of the world’s leading generic drugmakers but it struggles to meet sales expectations and faces tough competition.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK